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Background. Tuberculous meningitis (TBM) is a medical emergency, yet there are no standardized treatment guidelines for the 
medical or neurosurgical management of these patients and little data on neurocritical care. We conducted an international survey 
to understand current medical and neurosurgical TBM management and resource availability to provide baseline data needed for 
future multicenter trials addressing unanswered clinical research questions and the establishment of standardized guidelines.
Methods. An online survey of 77 questions covering medical and neurosurgical TBM management aimed at clinicians/nurses 
treating TBM was distributed as an anonymous link through email invitation, international organizations’ membership distribution, 
and direct links on organizational webpages or social media. The survey remained open for 5 months. Data were summarized with 
frequencies and percentages.
Results. The survey had 222 responses from 43 countries representing 6 continents. Most respondents were from tertiary care 
facilities, with broad access to medical and neurosurgical resources. There was significant heterogeneity in general supportive care, 
and TBM-specific management demonstrated considerable divergence from current standard-of-care practices. The lack of stand-
ardized guidelines was identified as a major challenge in TBM management. General and neurocritical care were largely absent. 
Resources for bedside supportive care and noninvasive monitoring were broadly accessible.
Conclusions. These findings suggest that current TBM management could be improved by the establishment of internationally 
accepted treatment guidelines based on available evidence, and that numerous centers have resources available to participate in fu-
ture multicenter trials, even for basic interventions, that may further improve patient outcomes globally.
Keywords.  international guidelines; neurocritical care; neurosurgery; survey; tuberculous meningitis.
Tuberculous meningitis (TBM) is the most fatal form of tu-
berculosis (TB) in adult and pediatric patients [1]. Treatment 
largely focuses on pharmacological intervention, including 
antibiotics and host-directed therapies. However, patient 
outcomes remain poor and treatment regimens are heteroge-
neous in terms of duration, dosing, and drugs used [2–7]. The 
treatment of TBM-associated hydrocephalus is also variable 
with some centers tailoring treatment based on whether the 
hydrocephalus is communicating, whereas others use surgical 
intervention uniformly [8, 9]. The evidence base to establish 
standardized medical and neurosurgical treatment guidelines is 
limited, and more work is required to establish comprehensive 
international guidelines.
Little to no investigation into supportive medical manage-
ment and neurocritical care strategies has been conducted for 
TBM, despite evidence of ongoing brain injury in patients re-
ceiving antibiotic and steroid therapy [10]. Research from other 
forms of brain injury demonstrates the benefit of neurocritical 
care to patient outcome [11]. Critical care involves monitoring 
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and responding to systemic variables (ie, temperature, nutrition, 
blood pressure) and cerebral variables (ie, intracranial pressure 
[ICP] and brain oxygenation), which can affect outcomes [12, 
13]. Application of similar critical care measures in TBM could 
potentially improve outcome, and warrant investigation [14].
We conducted a survey of the current medical and neurosur-
gical measures available and used internationally. The aim was 
to establish what practices are currently being used, the degree 
of heterogeneity thereof, and the availability of resources. To 
date, this information has not been gathered on a global scale 
and would be valuable for the establishment of evidence-based 
guidelines for the acute medical and neurosurgical manage-
ment of TBM through future multicenter research.
Participant Consent Statement
The survey began with written informed consent, and partici-
pants had to electronically indicate their willingness to partici-
pate. This survey was approved by the Johns Hopkins Medicine 
Institutional Review Board (IRB00152756) and the University of 
Cape Town Scientific and Human Research Ethics Committees 
(HREC 683/2017).
METHODS
The survey themes and questions were developed based on 
current management strategies in TBM and piloted by a group 
within the Tuberculous Meningitis International Research 
Consortium. The survey was compiled in English using the 
Qualtrics program (https://login.qualtrics.com/login) and was 
translated into Chinese by collaborators. The survey included 
76 questions in 12 sections; the first 2 sections covered dem-
ographics and resources, which enabled skip logic to show the 
participant only questions relevant to their resources. The re-
maining sections focused on acute medical and neurosurgical 
management in the first 2 weeks of presentation, including 
general questions, neuroimaging, laboratory acquisition, and 
management of hydrocephalus, hyponatremia, oxygenation/
ventilation, temperature, nutrition, hemoglobin, blood pres-
sure, and pharmaceuticals. Most questions were closed-ended 
but allowed participants to “check all that apply.” There were 4 
open-ended questions to allow respondents to enter their lo-
cation and to comment on topics not addressed by previous 
questions. Open-ended questions were analyzed using qualita-
tive directed content analysis to generate themes, and grouping 
was reached by consensus by 2 principal investigators [15]. The 
complete survey can be found in the Supplementary Material 
(Supplementary Text S1).
Distribution of the survey began on May 1, 2018 and in-
volved a combination of individual email invitations, interna-
tional organizations’ membership distribution, and direct links 
on organizational webpages or social media (ie, Twitter) via 
an anonymous link. The international organizations included 
the World Federation of Pediatric Intensive and Critical Care 
Societies (WFPICCS), World Federation Neurosurgery Society 
(WFNS), Pediatric Acute Lung Injury and Sepsis Investigators 
(PALISI)’s Global Health subgroup, International Society 
for Pediatric Neurosurgery (ISPN), Pediatric Neurocritical 
Care Research Group (PNCRG), Society of Neurosurgeons of 
South Africa (SNSA), German Society of Tropical Paediatrics 
and International Child Health (GTP), American Academy 
of Pediatrics’ Section on International Child Health (AAP 
SOICH), Pakistan Neurology Society (PNS), World Federation 
of Societies of Intensive and Critical Care Medicine (WFICC), 
and International Child Neurology Association (ICNA). Some 
authors were also survey respondents. The survey was closed on 
October 2, 2018.
Data were analyzed using IBM SPSS Statistics (IBM 
Corporation, Armonk, NY), and figures were made with 
CorelDRAW (Corel Corporation, Ottawa, CA). Respondent 
answers were summarized with frequencies and percentages for 
categorical variables. Partial responses were analyzed if ≥75% 
of questions were completed, but only surveys that were 100% 
completed had an identified location. Percentages were calcu-
lated based on the number of questions answered and appli-
cable to the respondents’ resource availability.
RESULTS
Survey Demographics
The survey was completed by 199 respondents from 43 coun-
tries representing 6 continents, with an additional 23 partial 
responses without a location included. South Africa, India, 
China, Indonesia, and Pakistan were the countries with the 
highest survey response (Figure  1 and Supplementary Table 
S1). The majority of participants were from tertiary care fa-
cilities in urban environments and almost half cared solely for 
children (Figure 2). Pediatric neurology (21.6%), neurosurgery 
(12.2%), adult infectious diseases (11.7%), and adult neurology 
(10.8%) were the top specialties, with >90% reporting active 
involvement in patient care (Supplementary Table S2). Half of 
respondents saw >11 patients a year, with 35% seeing >20 an-
nually (Figure  1 and Supplementary Table S2). Most patients 
were hospitalized for >10 days. Supplementary Table S2 lists all 
survey respondent demographics.
Resources Availability and Utilization
Table  1 summarizes the availability and utilization of re-
sources, with detailed information in Supplementary Material 
(Supplementary Tables S3 to S11). Laboratory studies, including 
blood, urine, and cerebrospinal fluid (CSF), were available to 
almost all participant sites and used largely at admission or 
when clinically indicated (Table 1 and Supplementary Table S3). 
Empiric diagnosis (based on clinical presentation, imaging, and/
or routine CSF characteristics) was most common in conjunction 
with culture, Gram stain/acid-fast bacilli smear, or polymerase 
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chain reaction (PCR), with the majority of PCR reported as 
GeneXpert (98%; Cepheid, Sunnyvale, CA). Neuroimaging was 
available to 90% of respondents, but admission imaging was 
performed by only 63%. Access to an intensive care unit (ICU) 
and to supportive noninvasive monitoring, such as blood pres-
sure, oxygenation (ie, pulse oximetry), and temperature, was 
common. When ICU care was available, respondents reported 
high patient to nurse ratios, low ICU admission rates, and bar-
riers to ICU care, most commonly bed shortage (Supplementary 
Table S11). Although currently there are no international guide-
lines available for TBM management, 40.5% of respondents 
reported access to a protocol for TBM, most commonly an insti-
tutional/hospital protocol (Supplementary Table S12).
Due to the high burden of disease and high survey response 
rate, a subanalysis of responses from tertiary care centers 
in China, India, and South Africa was performed for TBM-
specific resource availability and utilization (Table 2). Although 
access to neuroimaging, ICU care, and neurosurgical manage-
ment were similar across all 3 countries, South African centers 
used these resources less. In addition, centers in China (100%) 
and India (70.6%) more commonly reported managing patients 
according to a protocol, whereas this was reported in less than 
half of South African centers (40.7%).
General Supportive Management
The most common target values in medical management re-
ported by respondents demonstrated significant heterogeneity 
(see Supplementary Tables S5 for summary and S6 to S10 for 
complete lists).
Hemodynamics
Blood pressure could be monitored by almost all respond-
ents and was monitored several times per day (Tables  1 and 
Supplementary Tables S6). Hypotension was treated with fluid 
boluses or vasoactive medications, of which dopamine was the 
most common (Supplementary Table S6).
Oxygen/Ventilation
Pulse oximetry was more frequently available than end-tidal 
carbon dioxide (ETCO2) and used to monitor adequate ventila-
tion (Tables 1 and Supplementary Table S7). Nasal cannula/prongs 
were the most common respiratory support devices (Table 1).
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Figure 1. Survey respondent location and their reported patient burden. (A) Map of survey respondents, with red dot indicating location and size corresponding with number 
of respondents from each city. Darker blue indicates more responses per country. (B) Number of tuberculous meningitis patients per year cared for by respondents.
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Temperature
Temperature was frequently measured, at least every 
3–4 hours, by transcutaneous, ear, or oral thermometers 
(Tables  1 and Supplementary Table S8). Paracetamol and 
ibuprofen were commonly used to treat hyperpyrexia 
(Supplementary Table S8).
Nutrition
Nutrition was largely given orally or administered via na-
sogastric tube. Oral feeding safety was assessed by clinical 
exam or less commonly by a speech consultant or swallow 
















Figure 2. International distribution of respondents. Global maps demonstrating survey respondent distribution by (A) type of facility (primary, secondary, tertiary), (B) loca-
tion of facility (urban, rural), and (C) patient age (pediatric, adult, both).
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Table 1. Resource Availability and Utilization
Availability Utilization
Resource Yes (%) Yes (%) Frequency
Intensive Care Unit    
 Admission 183/222 (82.4) 129/183 (70.5)  
Noninvasive Monitoring Hourly Every 4 Hours
 Blood pressure 217/222 (97.7)  33/217 (15.2) 67/217 (30.9)
 Pulse oximetry 214/221 (96.8)    
 End-tidal carbon dioxide 143/219 (65.3) 95/143 (66.4)   
 Temperature 216/221 (97.7)  27/216 (12.5) 143/216 (66.2)
Respiratory Supporta
 None (room air)  77/217 (35.5)  
 Nasal cannula 211/221 (95.4) 100/211 (47.4)  
 High-flow nasal cannula 140/218 (64.2) 10/140 (7.1)  
 Continuous positive airway pressure 178/219 (81.3) 2/178 (1.1)  
 Bilevel positive airway pressure 153/218 (70.2) 2/153 (1.3)  
 Ventilator 192/220 (87.2) 22/192 (11.5)  
Medical Intervention
 Transfusion 213/222 (95.9) 167/213 (78.4)  
 Intravenous antibiotic 218/222 (98.2)  
 Intravenous antiretroviral 211/222 (95)  
Noninvasive Neuroimaginga Admission Only ≥2 Occasions 
 All imaging   127/202 (62.9) 124/202 (61.4)
 Computed tomography 203/222 (91.4) 166/203 (81.8)   
 Magnetic resonance imaging 172/222 (77.5) 117/172 (68)   
 Cranial ultrasound 148/220 (67.3) 22/148 (14.9)   
 Angiography 142/222 (63.9) 14/142 (9.9)   
 Ocular ultrasound 74/212 (34.9)    
Noninvasive Neuromonitoringa
 Near-infrared spectroscopy 38/215 (17.7)    
 Transcranial doppler 90/219 (41.1)    
 Electroencephalogram 132/220 (60)    
Neurosurgery 
 Consult 199/221 (90)  
Neurosurgical Interventiona Measure ICP Treat ICP 
 Ventriculoperitoneal shunt 167/222 (75.2)  122/167 (73.1)
 Lumbar drain 136/220 (61.8)  41/136 (30.1)
 Lumbar puncture  156/209 (74.6) 79/222 (35.6)
 External ventricular drain 135/220 (61.4) 71/135 (52.9) 107/135 (79.3)
 Endoscopic third ventriculostomy 109/217 (50.2)  47/179 (26.3)
Invasive Neuromonitoring
 Intraparenchymal intracranial pressure catheter 80/216 (37)   
 Partial brain tissue oxygen tension 29/215 (13.5)   
System Resources 
 Treatment protocol 90/222 (40.5)   
 Any medical record 160/222 (72)   
 Electronic medical record 62/222 (27.9)   
 Research database 76/222 (34.2)   
Blood Laboratory Testsa Admission If Clinically Indicated
 All laboratory tests 215/221 (97.2)   
 Basic metabolic profileb  107/214 (50) 78/214 (36.4)
 Liver function testc  103/214 (48.1) 86/214 (40.1)
 Kidney function testd  109/214 (50.9) 79/214 (36.9)
 Complete blood counte  117/220 (53.2) 79/220 (35.9)
 Blood gas  63/212 (29.7) 128/212 (60.4)
 Coagulationf  70/214 (32.7) 130/214 (60.7)
 Serum osmolality  29/211 (13.7) 127/211 (60.2)
 HIV testing   206/222 (92.8)
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Anaemia and Transfusion
Most respondents reported the ability to transfuse TBM pa-
tients, although the goal hemoglobin demonstrated heteroge-
neity across centers (Supplementary Tables S5 and S10).
Tuberculous Meningitis-Specific Management
Tuberculous meningitis-specific patient management was het-
erogeneous, and some respondents reported divergence from 
current standard of care as summarized in Table 3.
Pharmaceutical Management
Pharmaceutical  management included antibiotics, anti-
retrovirals (ARTs), corticosteroids, and other host-directed 
therapies (Supplementary Table S13). Approximately 70% 
of respondents used all first-line antibiotics (per the World 
Health Organization), and over 40% used at least 1 second-
line antibiotic, mostly fluoroquinolones [16]. Antibiotic du-
ration was commonly 12  months, and steroid duration was 
6 weeks usually with a 1- to 2-week taper. Most respondents 
waited 2 to 4 weeks after antibiotic initiation before starting 
ARTs in human immunodeficiency virus (HIV) coinfected 
patients; however, 11% did not. Corticosteroids were used by 
97% of respondents, although choice of corticosteroid was 
heterogeneous.
Intracranial Pressure and Hydrocephalus Management
More than 80% of respondents reported measuring ICP, mostly 
with a lumbar puncture ([LP] Table 1 and Supplementary Table 
S14). Lumbar punctures were most often repeated when clini-
cally indicated, although only 58.3% recorded opening pressure 
with each LP. Most respondents tested for communicating hy-
drocephalus, most commonly using imaging. Air encephalogram 
and a column test were less commonly used (Supplementary 
Table S14). Ventriculoperitoneal shunts and external ventric-
ular drains were the most common neurosurgical interventions 
for elevated ICP (Supplementary Table S14). Medical treatments 
of raised ICP included raising the head of the bed, seizure con-
trol, and hypertonic saline or mannitol, and less commonly tem-
perature control, diuretics, hyperventilation, and frequent LPs 
(Supplementary Table S14).
Hyponatremia Management
Clinical examination and urine output were used to deter-
mine fluid balance (Supplementary Figure S1A). Treatment 
Availability Utilization
Resource Yes (%) Yes (%) Frequency
Urine Laboratory Testsa Admission Clinically Indicated
 All laboratory tests 214/220 (97.2)   
 Urine sodium  12/211 (5.6) 131/211 (60.2)
 Urine osmolality  14/212 (6.6) 131/212 (61.8)
CSF Laboratory Testsa Admission Every LP Clinically Indicated
 All laboratory tests 215/222 (96.8)    
 Protein  141/213 (66.2) 79/213 (37) 66/213 (30.9)
 Cell count  140/213 (65.7) 78/213 (36.6) 65/213 (30.5)
 Glucose  140/212 (66) 79/212 (37.2) 65/212 (30.6)
 Gram stain/culture  143/212 (67.5) 78/212 (36.7) 66/212 (31.1)
TBM Diagnosticsa,g Admission
 Empiric  142/221 (64.2)
 Culture  133/221 (60.1)
 Gram stainh  113/221 (51.1)
 Polymerase chain reactioni  135/221 (61)
 Interferon gamma release assay  9/221 (4.1)
 Adenosine deaminase  2/221 (0.9)
 Biopsy  1/221 (0.5)
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; ICP, intracranial pressure; LP, lumbar puncture; TBM, tuberculous meningitis.
NOTE: The response “yes” to availability of resource combines respondents that answered “always” and “sometimes” to access. All blank cells reflect data that was not available or appli-
cable, such as frequency of utilization for continuous monitoring (eg, pulse oximetry).
aMore than 1 response was allowed per question.
bSodium, potassium, and glucose.
cAlanine transaminase and aspartate transaminase.
dCreatinine and blood urea nitrogen.
eFull blood count, hemoglobin, and platelet.
fProthrombin time and partial thromboplastin time.
gOnly utilization, not availability, of TBM diagnostic was surveyed here.
hGram stain includes acid-fast bacilli smear.
iAll but 4 of the polymerase chain reactions were GeneXpert (Cepheid, Sunnyvale, CA).
Table 1. Continued
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of hyponatremia was most often initiated for serum sodium 
<130 and hypertonic saline was most commonly used, irre-
spective of the underlying etiology (Supplementary Figure 
S1B and C). However, fluid restriction was more common in 
syndrome of inappropriate antidiuretic hormone ([SIADH] 
61.8%) than cerebral salt wasting ([CSW] 31.8%). Rarely, 
hyponatremia was treated with transfusions, fludrocortisone, 
or vasopressin/vasopressin receptor analogs (Supplementary 
Table S15 and Supplementary Figure S1C).
Open-Ended Questions
Three open-ended questions allowed respondents to highlight 
themes not addressed by the survey, with representative quotes 
listed in Supplementary Table S16.
“What other imaging, laboratory or clinical parameters do 
you monitor in TBM patients that were not previously asked 
about?”—Three themes emerged: (1) neurological clinical exam 
and neuromonitoring, (2) investigation of extrapulmonary 
sites, and (3) TB screening of contacts.
Table 2. TBM-Specific Resource Availability and Utilization in Tertiary Centers in China, India, and South Africa
Resource
China India South Africa
Yes (%) Yes (%) Yes (%)
Resource Availability
General
Intensive care unit 15/16 (93.8) 17/17 (100) 26/27 (96.3)
Treatment protocol 16/16 (100) 12/17 (70.6) 11/27 (40.7)
Noninvasive Neuroimaginga
Computed tomography 16/16 (100) 16/17 (94.1) 26/27 (96.3)
Magnetic resonance imaging 16/16 (100) 16/17 (94.1) 24/27 (88.9)
Neurosurgerya
Neurosurgery consult 15/16 (93.8) 17/17 (100) 26/27 (96.3)
Ventriculoperitoneal shunt 13/16 (81.3) 16/17 (94.1) 23/27 (85.2)
Lumbar drain 13/15 (86.7)* 14/17 (82.4) 18/27 (66.7)
External ventricular drain 15/16 (93.8) 15/17 (88.2) 20/27 (74.1)
Endoscopic third ventriculostomy 10/16 (62.5) 16/17 (94.1) 16/26 (61.5)*
Laboratory Tests
 All blood laboratory tests 16/16 (100) 16/17 (94.1) 26/27 (96.3)
 All urine laboratory tests 16/16 (100) 16/17 (94.1) 26/27 (96.3)
 All CSF laboratory tests 16/16 (100) 16/17 (94.1) 26/27 (96.3)
Resource Utilization
Noninvasive Neuroimaginga
Computed tomography 11/16 (68.8) 12/16 (75) 25/26 (96.2)
Magnetic resonance imaging 16/16 (100) 15/16 (93.8) 5/26 (19.2)
TBM Diagnosisa,b
Empiric 4/16 (25) 9/17 (52.9) 17/27 (63)
Culture 15/16 (93.8) 7/17 (41.2) 14/27 (51.9)
Gram stainc 16/16 (100) 5/17 (29.4) 9/27 (33.3)
Polymerase chain reactiond 10/16 (62.5) 10/17 (58.8) 14/27 (51.9)
ICP Monitoringa
External ventricular drain transduced 0/15 (0) 4/14 (28.6) 4/26 (15.4)*
Lumbar puncture 15/15 (100)* 12/14 (85.7) 26/26 (100)*
Intraparenchymal intracranial pressure catheter 0/15 (0) 5/14 (35.7) 1/26 (3.8)*
ICP Managementa
Ventriculoperitoneal shunt 10/14 (71.4)* 15/17 (88.2) 17/25 (68)*
External ventricular drain 11/14 (78.6)* 15/17 (88.2) 13/25 (52)*
Endoscopic third ventriculostomy 2/14 (14.3)* 7/17 (41.2) 5/25 (20)*
Lumbar drain 8/14 (57.1)* 3/17 (17.6) 2/25 (8)*
Lumbar puncture 8/16 (50) 4/17 (23.5) 16/27 (59.3)
Diuretics 15/16 (93.8) 10/17 (58.8) 12/27 (44.4)
Osmotics 16/16 (100) 16/27 (59.3) 16/27 (59.3)
Abbreviations: CSF, cerebrospinal fluid; ICP, intracranial pressure; TBM, tuberculous meningitis.
NOTE: The availability of resource combines respondents that answered “always” and “sometimes” to access.
aMore than 1 response was allowed per question.
bOnly utilization, not availability, of TBM diagnostics.
cGram stain includes acid-fast bacilli smear.
dAll but 1 of the polymerase chain reactions were GeneXpert (Cepheid, Sunnyvale, CA).
*Indicates questions for which some responses were missing.
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“What other treatments (that were not previously asked about) 
do you use in patients with TBM?”—The common themes were 
as follows: (1) additional antimicrobials, (2) other pharmaceu-
tical management, (3) ancillary support (ie, physical/occupa-
tional therapy and social work), and (4) supportive technology 
and/or invasive procedures (ie, biopsy/resection, dialysis, and 
gastrostomy tube).
“What are the biggest challenges facing your facility in man-
aging patients with TBM?”—Common concerns were as follows: 
(1) diagnostic challenges, (2) inadequate access to specialized 
neurosurgical/neurocritical care, (3) general lack of experi-
ence and standardized guidelines, (4) management of HIV and 
comorbidities, (5) antimicrobial management (ie, access, drug 
delivery/brain penetration, duration of therapy, drug resistance, 
compliance, and drug toxicities), (6) limited resources (human, 
physical, and financial), and (7) socioeconomic constraints.
DISCUSSION
The survey had broad global reach with representation from 
high-burden countries. Two main findings were as follows: 
(1) notable heterogeneity across all domains of TBM manage-
ment, including access and utilization of resources, with some 
respondents diverging from current standards of care; and (2) 
demonstration of geographic resource availability that could 
aid in future clinical trials to establish treatment guidelines. 
Persistent knowledge gaps in medical and neurosurgical care 
are summarized in Table 4, including clinical trials (both past 
and ongoing) and required resources to address these questions 
(see Supplementary Table S17 for expanded version of Table 4).
Access to Resources
This survey demonstrated that many laboratory tests, neu-
roimaging, and noninvasive monitoring were broadly acces-
sible. This provides a promising framework for future trials 
to address unanswered management questions, although trial 
funding would be needed to compensate for resource limita-
tions. Access to resources alone does not account for all varia-
bility in utilization, which was demonstrated by the subanalysis 
of China, India, and South Africa where South African tertiary 
centers used ICU care, neuroimaging, and neurosurgery less, 
possibly due to a higher burden on available resources. It is 
regrettable that few respondents reported using a research da-
tabase. Databases that can be shared across centers would be in-
valuable in the development of evidence-based guidelines, and 
approaches to standardize data and sample collection for com-
parison across centers have been published by the Tuberculous 
Meningitis International Research Consortium [17, 18].
Current Patient Management
Lack of standardized international TBM treatment protocols 
represents one of the “biggest challenges” in management. 
National or organizational protocols mentioned did not deal 
with supportive management, and few suggested neurosurgical 
intervention. Furthermore, as demonstrated in Table  3, nu-
merous respondents diverged from current standards of care in 
terms of diagnosis and clinical management. Despite almost uni-
versal access to laboratory investigations, one third of respond-
ents reported not testing CSF on admission. Cerebrospinal fluid 
is vital to the empiric and laboratory diagnosis of TBM and 
raises the question of whether there is over- and underdiagnosis 
of TBM. Likewise, neuroimaging is key to empiric diagnosis 
and the assessment of hydrocephalus, yet it was used by only 
63% of respondents, although it was accessible to 91%. In ad-
dition, only 78% of respondents used all 4 first-line antibiotics 
for drug-susceptible TBM and 3% did not use corticosteroids, 
although this is the internationally accepted standard of care. 
Furthermore, 11% of respondents initiated ART simultaneously 
with antibiotics, even though this is known to increase the risk 
of an immune reconstitution inflammatory syndrome response 
in ART-naive patients [19]. These departures from the standard 
of care could be a symptom of the absence of internationally ac-
cepted guidelines. It is interesting to note that in the subanalysis 
of tertiary centers across China, India, and South Africa, China 
and India reported broader use of treatment protocols and 
more uniform use of resources. Establishment of clear guide-
lines for optimal TBM management could improve care now 
and in the future.
Addressing Unanswered Clinical Research Questions
Pharmaceutical Care
Survey data show heterogeneity in the choice of antibiotics, 
route of administration, dosage, and duration of treatment. 
Similarly host-directed therapies were used variably. Numerous 
studies to address these questions are already underway 
(Table 4), and findings suggest that higher doses of rifampicin 
and intravenous administration may be beneficial [3, 20, 21]. 
Work on corticosteroids aims to understand how they improve 
mortality and determine whether host-associated characteris-
tics play a role. In HIV-coinfected patients, research on how to 
optimally incorporate steroids in the treatment regimen is on-
going. New additions to host-directed therapy such as aspirin 
are being tested, and novel targets are likely to be elucidated by 
further research [22].
Neurocritical and Supportive Care
Supportive general and neurocritical care are the standard of 
care for numerous forms of brain injury [11–13]. However, 
it appears rare in TBM despite the high rate of neurolog-
ical injury, and respondents reported this lack of specialized 
neurocritical care as one of the biggest challenges to TBM man-
agement. Neurocritical care is not limited to the ICU and can 
include basic, but effective, treatment at ward level. Resources 
for bedside supportive management and noninvasive moni-
toring were available in most respondents’ centers. Therefore, 
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Table 4. Outstanding Clinical Research Questions in the Medical and Surgical Management of TBM
Clinical 





• What is the optimal antibiotic regimen 
for TBM?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦	Serum and CSF  
collection
	 ◦	Te Brake et al [20]; Ruslami et al [3]; Dian et al [21]; 
Heemskerk et al [4]
• What is the optimal dose in adults 
and children?
	 ◦Long-term sample storage • Ongoing Study by Clinical Trial Name
	 ◦Drug concentration analysis 	 ◦	Optimizing Antituberculosis Therapy in Adults with Tubercu-
lous Meningitis; TBM-KIDS; INTENSE-TBM; LASER-TBM; 
ALTER; SIMPLE; Harvest Trial—Improving Outcomes 
from TB Meningitis with High Dose Oral Rifampicin; Is 
Levofloxacin Better than Rifampicin in the Treatment of 
Tuberculous Meningitis, a Randomized Control Study; ES-
CALATE; High Dose Oral and Intravenous Rifampicin for 
Improved Survival of Adult Tuberculous Meningitis: a Phase 





• What is the optimal treatment dura-
tion in adults and children?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Reviewed in Jullien et al [33]c
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Antibiotics 	 ◦	SURE; Determination of Efficacy of 9 Months, 12 Months 
and 18 Months of Anti-tubercular Treatment (ATT) for Tu-
berculous Meningitis (TBM): a Randomized Controlled, 
Noninferiority Trial 
Antibiotic  
route of  
administra-
tion
• What is the optimal route of adminis-
tration, oral or intravenous?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Ruslami et al [3]
•  Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Antibiotics 	 ◦	LASER-TBM; High Dose Oral and Intravenous Rifampicin for 
Improved Survival of Adult Tuberculous Meningitis: a Phase 




• What is the optimal timing of ART 
initiation?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Török et al [19]; Laureillard et al [34]d
• Pharmaceuticals • Ongoing Study by Clinical Trial Name




• What is the optimal duration of corti-
costeroid use?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Török et al [35]
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
 ◦Corticosteroids 	 ◦	Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Cor-
ticosteroids for HIV-uninfected Adults with Tuberculous 




• What is the optimal route of adminis-
tration, oral or intravenous?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦None
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Corticosteroids 	 ◦	Comparison of Regimens of Dexamethasone in Tubercular 
Meningitis—a Randomized Control Trial
Corticosteroid 
taper
• What is the optimal duration of corti-
costeroid taper?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦None
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Corticosteroids 	 ◦None
Aspirin • What is the role of aspirin as a  
host-directed therapy?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Mai et al [22]; Schoeman et al [6]e
• What is the optimal dose and duration? • Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Aspirin 	 ◦INTENSE-TBM; LASER-TBM; SURE
Thalidomide • What is the role of thalidomide as a 
host-directed therapy?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦Schoeman et al [7]e
• What is the optimal dose and dura-
tion?
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Thalidomide 	 ◦None
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Clinical 




• What is the role of other host-directed 
therapies in TBM?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦As above 	 ◦None
• Pharmaceuticals • Ongoing Study by Clinical Trial Name
	 ◦Other (ie, Indomethacin) 	 ◦	An Open Label Randomized Study to Evaluate Effectiveness 
of Indomethacin in Tuberculous Meningitis
Intracranial Pressure (ICP) Management 
ICP manage-
ment
• How should ICP be measured? • Neurosurgical Expertise • Past Publications (Clinical Trial Name)
• How frequently should ICP be measured? 	 ◦ICP monitoring 	 ◦None
• How should ICP be managed? • Neuromonitoring • Ongoing Study by Clinical Trial Name
• What is the optimal ICP target in 
TBM?
	 ◦ICP (brain oxygenation) • None 
• Neuroimaging
• Should the target be age specific? • Equipment
	 ◦Manometer
• Cardiovascular Monitoring
	 ◦Blood pressure, heart rate
• Pharmaceuticals




• How should communicating vs non-
communicating hydrocephalus be 
diagnosed?
• Neurosurgical Expertise • Past Publications (Clinical Trial Name)
• Neuroimaging 	 ◦None
	 ◦CT, MRI, X-ray (skull) • Ongoing Study by Clinical Trial Name







• What should be the standard of care 
in medical and surgical management 
of hydrocephalus?
• Neurosurgical Expertise • Past Publications (Clinical Trial Name)
	 ◦Surgical intervention 	 ◦None
• Neuromonitoring • Ongoing Study by Clinical Trial Name
	 ◦ICP monitor 	 ◦None










• How should the etiology of 
hyponatremia be investigated?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦Electrolytes (serum/urine) 	 ◦Misra et al [28]; Misra et al [36]c
• Fluid Balance Monitoring • Ongoing Study by Clinical Trial Name




• What should be the standard of care 
in hyponatremia management when 
etiology is cerebral salt wasting or 
syndrome of inappropriate antidiuretic 
hormone?
• Laboratory • Past Publications (Clinical Trial Name)
	 ◦Electrolytes (serum/urine) 	 ◦Misra et al [37]
• Fluid Balance Monitoring • Ongoing Study by Clinical Trial Name
	 ◦Invasive or noninvasive 	 ◦None
• Pharmaceuticals





• How should temperature be moni-
tored and frequency?
• Temperature Monitoring • Past Publications (Clinical Trial Name)
	 ◦	Continuous or 
noncontinuous
	 ◦None
• What is the target temperature and 
how should temperature be man-
aged?





sure (BP)  
manage-
ment
• How should BP be monitored? • Blood Pressure Monitoring • Past Publications (Clinical Trial Name)
• What is the target BP? 	 ◦Invasive or noninvasive 	 ◦None
• How should BP be managed? • Neuromonitoring • Ongoing Study by Clinical Trial Name




12 • ofid • Tucker et al
basic interventions could be feasible for TBM-endemic set-
tings (Table 4). For example, blood pressure, pulse oximetry, 
and temperature monitoring are widely available, suggesting 
that goals to avoid hypotension, hypoxia, and hyperpyrexia 
could be investigated. Although TBM is often characterized 
by weight loss and malnutrition affects antibiotic pharmacoki-
netics, TBM studies investigating early feeding or avoidance of 
hyperglycemia have not been done despite their ability to im-
prove outcomes in TBI [23, 24]. Data to establish the benefit 
of simple interventions like these in TBM may require clinical 
trials in better-resourced environments, but their application 
would be broadly appropriate. Until a sufficient evidence base 
for the neurocritical and supportive care of TBM can be estab-
lished, a checklist may be a beneficial first step [25].
Although 84% of respondents reported measuring ICP, fewer 
reported how this was done and <50% regularly recorded the 
opening pressure, suggesting that ICP is not systematically 
measured (Supplementary Table S14). Given the prevalence of 
hydrocephalus with associated raised ICP, these data suggest 
a need for protocols to monitor ICP, including location, fre-
quency of measurement, and treatment thresholds (Table  4) 
[26]. Medical interventions for raised ICP, such as raising the 
head of the bed, controlling seizures, and utilizing osmotic 
agents, were reported by 70%–80% of respondents and could 
therefore be studied more systematically.
Differentiating between SIADH and CSW as the etiology 
of hyponatremia is a challenging but important step to imple-
ment appropriate intervention due to their divergent treatment 
(Table  4 and Supplementary Figure 1) [9]. Hypertonic saline 
may be a suitable treatment for both conditions, and our data 
demonstrate its frequent use [9]. However, 30% of respondents 
used fluid restriction even when they did not suspect SIADH. 
Furthermore, although respondents considered SIADH to be 
the predominant etiology, recent studies have demonstrated 
that CSW occurs more frequently in TBM and is associated 
with severe infarction [27, 28]. Multicenter studies to establish 
a recommended diagnostic approach for SIADH and CSW, and 
trial treatment options are needed.
Neurosurgical Care
Currently there is limited evidence for the nature and timing 
of neurosurgery for TBM hydrocephalus [8]. Consequently, 
practices are heterogeneous and accurate data on neurosur-
gical complications and success rates are lacking. The use of 
shunts or endoscopic third ventriculostomy and the selec-
tion of patients most likely to benefit requires multicenter 
study. Many respondents used imaging to test for hydro-
cephalus communication, yet there are no data that support 
the accuracy of imaging in determining this. The rele-
vance, diagnosis, and advantages of medical versus surgical 
Clinical 




• How should ventilation/oxygenation 
be monitored and managed?
• General Monitoring • Past Publications (Clinical Trial Name)
	 ◦BP, pulse oximetry 	 ◦None
• Neuromonitoring • Ongoing Study by Clinical Trial Name
• What is the target end-tidal carbon 
dioxide level (ETCO2)?
	 ◦Consider brain oxygenation 	 ◦None
• Equipment
	 ◦	Ventilator, nasal cannula, 
ETCO2, arterial blood gas




• How should seizures be monitored? • Noninvasive Monitoring • Past Publications (Clinical Trial Name)
	 ◦Temperature, EEG 	 ◦None
• How should seizures be managed? • Neuromonitoring • Ongoing Study by Clinical Trial Name




Abbreviations: ATT, antitubercular treatment; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; CT, computed tomography; EEG, electroencephalogram; HIV, human immunodefi-
ciency virus; MRI, magnetic resonance imaging; RCT, randomized controlled trial; TBM, tuberculous meningitis.
NOTE: Summary of outstanding questions regarding the medical management of TBM, the necessary resources, and relevant past and ongoing RCTS. Previous clinical trials and their asso-
ciated publications highlight RCTs and publications since 2010 unless no RCTs exist or only earlier studies are available.
aAdditional resources are those beyond resources for diagnosis, patient management (general clinical care, monitoring, and staff), trial support.
bIn Supplementary Table S17, RCT acronyms are spelled out and listed with clinical trial identifier and reflect those registered by the National Institutes of Health’s US National Library of 
Medicine (clinicaltrials.gov) or World Health Organization’s International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/Default.aspx).
cNo RCTs available.
dThis RCT included all patients with TB, including pulmonary and TBM.
eNo clinical trial identifier available but included due to paucity of data in pediatrics.
Table 4. Continued
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management of hydrocephalus communication warrant in-
vestigation (Table 4) [9].
Limitations
Responses were largely from tertiary centers and may not re-
flect the rural and primary/secondary setting. However, the 
data show that most referrals are to tertiary centers. The use 
of organizational contacts within the TBM field could have 
contributed to sampling bias, and this likely skewed the data 
by the high number of respondents from neurosurgery, pe-
diatrics, and South Africa, although wide distribution of the 
survey was available on social media. This is unlikely to have 
obscured the heterogeneity of management protocols or re-
source access, but neurosurgical treatment for hydrocephalus 
may be overrepresented. In addition, other complications, such 
as drug-induced liver toxicity or paradoxical reactions, may 
have revealed similarly heterogenous management but were be-
yond the scope of this survey. We were unable to determine the 
survey hit rate due to the use of an anonymous link and utiliza-
tion of list-serve distribution. Survey completion was subjective 
and consistency in intraindividual respondent answers cannot 
be guaranteed. Due to resource constraints, we were not able to 
translate this survey into multiple languages. However, English 
is commonly used by medical professionals worldwide. We 
were unable to back-translate the Chinese version, but answers 
were entered directly into the Qualtrics program to maintain 
response format.
CONCLUSIONS
The management of TBM is highly variable, even with respect 
to current standard of care, and the use of neurocritical care 
is limited. Numerous sites have access to important resources 
to participate in single-center and multicenter clinical trials to 
establish evidence-based treatment guidelines and investigate 
the value of supportive medical and neurosurgical measures on 
patient outcomes. Guidelines based on current evidence could 
help improve management now, and serve as the framework on 
which to build.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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